| Autor: |
M L, Lopresti, J J, Bian, B J, Sakr, R S, Strenger, R D, Legare, M, Fenton, S M, Witherby, D S, Dizon, S V, Pandya, A R, Stuckey, D A, Edmondson, J S, Gass, C M, Emmick, T A, Graves, M, Cutitar, A J, Olszewski, W M, Sikov |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Breast cancer research and treatment. 189(1) |
| ISSN: |
1573-7217 |
| Popis: |
In HER2-positive breast cancer (HER2+ BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response (pCR) rates. Anthracycline-free NACT regimens avoid toxicities associated with anthracyclines, but every 3-week TCHP also has substantial side effects. We hypothesized that a weekly regimen might have equivalent efficacy with less toxicity; we also investigated whether poorly responding patients would benefit from switching to AC.Patients with clinical stage II-III HER2+ BC received weekly paclitaxel 80 mg/mIn 30 evaluable patients, the pCR rate was 77% (95% CI 58-90%); 12/14 (86%) in ER-negative and 11/16 (69%) in ER-positive. Only two patients transitioned to AC for non-response, of which one achieved pCR. There were no episodes of febrile neutropenia or grade ≥ 3 peripheral neuropathy, though several patients who continued wPCbTP stopped before week 18. Split-dose pertuzumab was associated with less grade ≥ 2 diarrhea (40%) than the standard loading dose (60%).pCR rates with our regimen were as high as reported with TCHP with fewer grade ≥ 3 toxicities, though diarrhea remains a concern. Too few patients had a suboptimal response to adequately test switching to AC. The wPCbTP regimen should be considered an alternative to TCHP as neoadjuvant therapy for HER2+ BC.ClinicalTrials.gov identifier: NCT02789657. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink